Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Renal failure caused by plasma cell infiltration in multiple myeloma.

Hanawa S, Akimoto T, Uehara E, Inoue M, Imai T, Kotoda A, Yoshizawa H, Matsuyama T, Ueda M, Saito O, Hamano Y, Yumura W, Ozawa K, Muto S, Kusano E.

Clin Exp Nephrol. 2011 Aug;15(4):586-90. doi: 10.1007/s10157-011-0437-x. Epub 2011 Mar 25.

PMID:
21437577
2.

[Successful steroid therapy for indolent myeloma with kidney injury due to direct infiltration of myeloma cells].

Tanaka T, Maeda Y.

Nihon Jinzo Gakkai Shi. 2015;57(7):1241-7. Japanese.

PMID:
26665616
3.

Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.

Gharwan H, Truica CI.

Med Oncol. 2012 Jun;29(2):1197-201. doi: 10.1007/s12032-011-9938-4. Epub 2011 Apr 9.

PMID:
21479696
4.
5.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M.

Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.

6.

[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].

Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, Ueda Y, Fujisaki T.

Gan To Kagaku Ryoho. 2011 Feb;38(2):237-41. Japanese.

PMID:
21368487
7.

Monotypic plasma cell interstitial nephritis as the only clinical manifestation in a patient with previously undiagnosed indolent multiple myeloma: A case report.

Attias P, Moktefi A, Matignon M, Dupuis J, Debiais-Delpech C, Grimbert P, Lang P, Audard V.

Medicine (Baltimore). 2016 Aug;95(31):e4391. doi: 10.1097/MD.0000000000004391.

8.

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E.

Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059.

PMID:
19717380
9.

[Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].

Xu Y, An G, Deng SH, Sui WW, Feng XY, Li F, Hao M, Wang YF, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):304-8. doi: 10.3760/cma.j.issn.0253-2727.2013.04.012. Chinese.

PMID:
23668201
10.
11.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

12.

Pathogenesis and treatment of renal failure in multiple myeloma.

Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H.

Leukemia. 2008 Aug;22(8):1485-93. doi: 10.1038/leu.2008.131. Epub 2008 Jun 5. Review.

PMID:
18528426
13.

IgA-kappa type multiple myeloma affecting proximal and distal renal tubules.

Minemura K, Ichikawa K, Itoh N, Suzuki N, Hara M, Shigematsu S, Kobayashi H, Hiramatsu K, Hashizume K.

Intern Med. 2001 Sep;40(9):931-5.

14.

Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.

Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, Levi A, Cartoni C, Musto P, Alimena G.

Clin Adv Hematol Oncol. 2012 Apr;10(4):266-8. No abstract available.

PMID:
22706491
15.

Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy.

Yamaguchi W, Yui N, Nagao T, Oshikawa G, Negi M, Iimori S, Okado T, Rai T, Uchida S.

Intern Med. 2016;55(3):263-8. doi: 10.2169/internalmedicine.55.5310. Epub 2016 Feb 1.

16.

[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].

Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G.

Presse Med. 2012 Mar;41(3 Pt 1):276-89. doi: 10.1016/j.lpm.2011.11.008. Epub 2012 Jan 13. Review. French.

PMID:
22244725
17.

Current treatments for renal failure due to multiple myeloma.

Kastritis E, Terpos E, Dimopoulos MA.

Expert Opin Pharmacother. 2013 Aug;14(11):1477-95. doi: 10.1517/14656566.2013.803068. Epub 2013 May 25. Review.

PMID:
23705905
18.

[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].

Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1146-50. Chinese.

PMID:
17204182
19.

[Fanconi syndrome in an adult coincident with early myeloma with monoclonal IgG, type kappa, anomaly (author's transl)].

Walb D, Wohlenberg H, Rumpelt HJ, Schmidt H, Thomas L.

Dtsch Med Wochenschr. 1980 Sep 26;105(39):1355-9. German.

PMID:
6257469
20.

[Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].

Cao ZG, Liu M, Zhou HW.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jan;34(1):74-5. Chinese. No abstract available.

PMID:
23597473

Supplemental Content

Support Center